Fig. 6.
Activity of SCH66336 in a murine model of BCR/ABL-induced acute lymphoblastic leukemia.
(A) Survival of mice injected with indicated doses of BCR/ABL-BaF3 cells. (B) Survival of mice injected with 106 BCR/ABL-BaF3 cells and treated with either vehicle alone or SCH66336. Treatment was stopped after 32 days. All mice that did not receive SCH66336 died of a condition resembling acute leukemia by 28 days; nearly all mice treated with SCH66336 survived for more than 1 year and remain disease-free.
